Univariate analysis of baseline clinical characteristics identified that the etiology, mALBI grade, and AFP level were contributing factors for better PFS in u‐HCC patients treated with Atezo+Bev (p = 0.07, p = 0.0058, and p = 0.06, respectively) (Table 6). This evidence concerns the gene AFP and hepatocellular carcinoma.